Clinical trials: Cerebral Metastases
Epilepsy With POS With or Without Secondary Generalization
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard…
- Trial name
- BASE (NCT02687711)
- Where
- 44 sites in Denmark, Germany and 7 more
- Volunteers
- 544 people
- Sponsor
- UCB Biopharma S.P.R.L.
Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers (NHVs) that uses an Integrated Protocol Design.
- Conditions
- Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis), Intracranial Arteriosclerosis
- Trial name
- NCT04103034
- Testing
- BT200, Desmopressin
- Where
- Austria
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Band Therapeutics
Epilepsy
Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
Patients with focal epileptic seizures with or without generalization who are at present treated with one or two antiepileptic drugs are eligible for this study, provided that they fulfill all inclusion criteria and none of the…
- Trial name
- NCT00165828
- Testing
- Zonegran
- Where
- 30 sites in Germany
- Volunteers
- 157 people
- Sponsor
- Eisai GmbH
Traumatic Brain Injury
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
The study is intended to cover two purposes: first, to develop a blood-based biomarker test for aiding the diagnosis of traumatic brain injury (TBI) in adult participants and for prognosis of outcome of TBI (CLIN12.1); and…
- Trial name
- NCT07455136
- Testing
- Blood sample collection
- Where
- 14 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04700072
- Testing
- Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Non-Small Cell Lung Cancer, Brain Metastases
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
The purpose of this study is to evaluate the efficacy of icotinib in combination with radiotherapy for NSCLC patients with brain metastases. The primary endpoint is PFS of intracranial lesions
- Trial name
- NCT03754530
- Testing
- Icotinib, WBRT or SRS
- Volunteers
- 162 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Stroke
"Evaluation Of ALBA® Device for Upper Extremity Motor Function In Adults With Subacute And Chronic Acquired Brain Injury"
As part of the rehabilitation techniques, robotic equipment has been introduced for the rehabilitation of the upper extremity with promising results.
- Trial name
- NCT05824416
- Testing
- Experimental: ALBA, Conventional Therapy
- Where
- Chile
- Volunteers
- 32 people
- Sponsor
- uMov
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Medication Overuse Headache
Pilot Study of DFN-11 Injection in Medication Overuse Headache
Efficacy and Safety Pilot Study of DFN-11 Injection in Medication Overuse Headache
- Trial name
- NCT02583425
- Testing
- DFN-11 Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dr. Reddy's Laboratories Limited
NSCLC, EGFR Activating Mutation
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.
- Conditions
- NSCLC, EGFR Activating Mutation, Brain Metastases
- Trial name
- NCT05948813
- Testing
- TY-9591, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- TYK Medicines, Inc
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Refractory Epilepsy
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
This is a Phase 2 double-blind, randomized, placebo-controlled study to assess the safety and efficacy of ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in subjects with focal…
- Trial name
- NCT04153175
- Testing
- ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
- Where
- 11 sites in Australia, Israel
- Volunteers
- 30 people
- Sponsor
- Cerebral Therapeutics LLC
Breast Cancer, Brain Metastases
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from breast cancer.
- Trial name
- GRABM-B (NCT01480583)
- Testing
- GRN1005, Trastuzumab, 18F-FLT
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Angiochem Inc
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Partial Onset Seizures, Epilepsy
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.
- Trial name
- NCT03836924
- Testing
- Perampanel
- Where
- 12 sites in India
- Volunteers
- 200 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Intracerebral Hemorrhage
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
- Trial name
- BIRCH (NCT05970224)
- Testing
- Ir-CPI
- Where
- 8 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Bioxodes S.A.
Non-small Cell Lung Cancer (NSCLC)
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
A clinical study to investigate the maximum tolerated dose of Vandetanib and concurrent WBRT in patients with NSCLC and brain metastases. All patients will receive WBRT, 10 fractions of 3 Gy.
- Trial name
- NCT00807170
- Testing
- ZD6474 (Vandetanib), Whole Brain Radiotherapy (WBRT), ZD6474
- Where
- 3 sites in Netherlands
- Volunteers
- 5 people
- Sponsor
- Sanofi